AU
UK
CA
NZ
IND
US
RetailerGap Inc. (NYSE: GPS)received a rating and price target upgrade from broker Wells Fargo. Praising clothing retailer Gap’s turnaround story, Wells Fargo raised its rating on the stock from ‘equal weight’ to ‘overweight’.
Brokerage house Citi has increased its rating on gene editing companyEditas Medicine (NASDAQ: EDIT)from 'neutral' to 'buy'. The broker believes that there exists the potential for a positive short-term stock price rise on two key catalysts through the end of the year.
Construction firmDycom Industries Inc. (NYSE: DY)received a rating upgrade from broker Raymond James, causing the stock price to rise by around 2% to US$83.78 on Friday. The rating upgrade came based on the forecast rise of AT&T, a key client of Dycom’s.
Broker Morgan Stanley upgraded its view on the clean tech industry, stating the stock selloff caused by concerns of higher interest rate as the main reason to do so. The broker upgraded some of the stocks in the industry, centered around this positive outlook.
Colgate-Palmolive (NYSE: CL), the manufacturer of toothpaste, experienced a 1.4% increase in its stock value, reaching US$71.9, following a rating upgrade by Stifel from 'hold' to 'buy.' Stifel is optimistic about the company's organic sales growth in FY23.
Broker Needham recently raised its ratings on semiconductor manufacturersApplied Materials (NASDAQ: AMAT) and Lam Research Corp. (NASDAQ: LRCX). Needham upgraded both stocks to ‘buy’ from ‘hold’.
General merchandise retailerTarget Corp. (NYSE: TGT)received a rating upgrade from broker BofA. TGT price rose by around 3% post the rating upgrade from BofA on October 12, 2023.
Biopharmaceutical firmNeumora Therapeutics (NASDAQ: NMRA)received a ‘buy’ rating from brokers shortly after its recent listing on the stock market. The stock debuted on the market last month and its price has declined by 28.5% since then.
Broker BofA increased its price target onEli Lilly and Company (NYSE: LLY), a pharmaceutical firm with its key areas of focus being neuroscience, cancer, and immunology. Eli Lilly’s market cap stood at over US$500 billion on Friday
Brokerage RBC initiated its coverage onJohnson & Johnson (NYSE: JNJ), giving the stock an ‘outperform’ rating. The broker et its price target at US$178, an upside potential of over 13% over Thursday’s closing price.
Please wait processing your request...